Jennifer Shaffer
Pulmonary Disease · Fort Wayne, INNPI 1831358597
Payments from drug & device makers
Across 56 payments — averaging $145.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$216
- Johnson & Johnson$188
- Boehringer Ingelheim$97
- GSK$93
- UCB, Inc.$54
- plus $484 from 17 others
What the payments were for
- Travel & lodging$1,13414%
- Food & beverage$95812%
- Education$6,04874%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $7,008 |
| AstraZeneca | 12 | $216 |
| Johnson & Johnson | 3 | $188 |
| Boehringer Ingelheim | 4 | $97 |
| GSK | 6 | $93 |
| UCB, Inc. | 1 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Philips North America LLC | 3 | $52 |
| Genentech USA, Inc. | 1 | $48 |
| Insmed, Inc. | 2 | $35 |
| Novartis | 2 | $34 |
| Amgen | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $26 |
| Abiomed | 1 | $25 |
| Baxter Healthcare | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $18 |
| Sanofi | 1 | $17 |
| Bayer | 1 | $17 |
| Shionogi Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,972
- ION$3,000
- Monarch Platform$143
How this compares
$8,140 in reported general payments places this provider in the 70th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 405 | $359,641 |
| Dupixent PenDupilumab | 32 | $123,120 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 81 | $56,719 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $47,431 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $46,682 |
| Spiriva RespimatTiotropium Bromide | 37 | $30,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $19,841 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 33 | $18,572 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $15,065 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $13,735 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 115 | $11,452 |
| Arnuity ElliptaFluticasone Furoate | 18 | $7,105 |
| Roflumilast | 77 | $5,736 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $5,559 |
| Epinephrine | 14 | $4,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $93 | $470,147592 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $97 | $96,406140 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $216 | $34,90675 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Fort Wayne
- Daria LeeFort Wayne$80K
- Vicente RodriguezFort Wayne$43K
- Abhishek BiswasFort Wayne$30K
- Bharat BajantriFort Wayne$29K
- Vatche IsrabianFort Wayne$22K
- Shivu KaushikFort Wayne$10K
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.